Analysts Expect Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Will Post Quarterly Sales of $12.76 Million

Brokerages forecast that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will post sales of $12.76 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Adamas Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $12.34 million and the highest estimate coming in at $13.60 million. Adamas Pharmaceuticals reported sales of $7.57 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 68.6%. The firm is scheduled to report its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full year sales of $55.10 million for the current financial year, with estimates ranging from $53.50 million to $58.50 million. For the next fiscal year, analysts forecast that the company will report sales of $100.84 million, with estimates ranging from $80.61 million to $123.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.05. The firm had revenue of $11.67 million during the quarter, compared to the consensus estimate of $12.78 million. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%.

A number of research analysts recently weighed in on ADMS shares. HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the company a “buy” rating in a report on Tuesday, May 28th. Mizuho restated a “buy” rating and set a $37.00 price objective on shares of Revance Therapeutics in a research note on Wednesday, April 24th. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday, July 10th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. Adamas Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $18.91.

Shares of ADMS stock traded down $0.02 during mid-day trading on Friday, hitting $5.99. 881,349 shares of the company’s stock were exchanged, compared to its average volume of 307,254. Adamas Pharmaceuticals has a fifty-two week low of $4.20 and a fifty-two week high of $29.49. The company has a 50-day simple moving average of $5.37. The company has a current ratio of 7.03, a quick ratio of 6.86 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $164.91 million, a PE ratio of -1.23 and a beta of 1.72.

A number of large investors have recently modified their holdings of the stock. Macquarie Group Ltd. lifted its stake in shares of Adamas Pharmaceuticals by 51.7% in the fourth quarter. Macquarie Group Ltd. now owns 2,708,217 shares of the specialty pharmaceutical company’s stock valued at $23,128,000 after buying an additional 923,099 shares during the period. Deltec Asset Management LLC grew its stake in shares of Adamas Pharmaceuticals by 127.4% during the first quarter. Deltec Asset Management LLC now owns 536,836 shares of the specialty pharmaceutical company’s stock valued at $3,817,000 after purchasing an additional 300,712 shares during the last quarter. Millennium Management LLC boosted its stake in Adamas Pharmaceuticals by 91.6% in the fourth quarter. Millennium Management LLC now owns 479,899 shares of the specialty pharmaceutical company’s stock valued at $4,098,000 after acquiring an additional 229,404 shares during the last quarter. Deutsche Bank AG boosted its stake in Adamas Pharmaceuticals by 506.7% in the fourth quarter. Deutsche Bank AG now owns 274,050 shares of the specialty pharmaceutical company’s stock valued at $2,339,000 after acquiring an additional 228,883 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in Adamas Pharmaceuticals by 9.3% in the fourth quarter. BlackRock Inc. now owns 2,064,758 shares of the specialty pharmaceutical company’s stock valued at $17,633,000 after acquiring an additional 174,844 shares during the last quarter. Hedge funds and other institutional investors own 76.68% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Featured Story: Elliott Wave Theory

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit